How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Indonesia?

Under Indonesia's medical device registration framework, authorized representative responsibilities are divided among three parties: the foreign manufacturer remains accountable for the safety, performance and quality system of the device and for the accuracy of the technical documentation; the Indonesian authorized representative or local license holder is accountable for regulatory submissions, communication with the national regulator, certificate maintenance, variation and renewal filings, and post-market incident reporting; and the local importer or distributor is accountable for importation, storage, distribution records and traceability. These boundaries should be fixed in a written mandate and an authorization letter before submission, because they determine who controls the registration certificate and who carries the ongoing compliance obligations.

Key Summary

Before a company can answer how authorized representative responsibilities are divided for Indonesian medical device registration, it should first confirm the target country, the product risk class, the applicable regulatory pathway and the documentation already available. Only then can it assess technical files, quality system evidence, labelling and instructions for use, local agency arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete files or ambiguous authorization arrangements do not extend the project timeline.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then decide whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Indonesian registration typically affects technical files, authorized representation, importer cooperation, label language, quality system evidence and subsequent change control at the same time. If a project is driven only by the question of which documents must be submitted, deficiencies and rework are likely to appear in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends positioning this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documentation country by country.

This article is compiled from AIMEILI's registration practice question bank, its medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and on the manufacturer's existing documentation.

Scope of Application and Core Questions

Companies searching for how authorized representative responsibilities are divided for medical device registration in Indonesia are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support an Indonesian submission, whether a local agent or authorized representative is required, why timelines are being extended, and which issues could affect the launch plan. Behind this question there are usually several interconnected factors: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility.

If a company plans to enter several GHWP member states at the same time, or markets in Southeast Asia, the Middle East and Latin America, answering the process for a single country is not enough. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, clinical setting, type and duration of body contact, sterility, whether the device is active, and whether it contains software or has an IVD attribute. Risk class and submission pathway follow from these answers. Once the pathway is wrong, all subsequent translation, notarization, authorization, testing and supplementary submissions will move in the wrong direction.

For an Indonesian project, the applicant entity and the local responsibility boundaries must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who initiates changes, and who maintains renewal documentation. If these points are left vague in a commercial contract, control over the market can be compromised later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance information.

The key to documentation quality is not volume but consistency. Statements in the instructions for use, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information on the registration application form must all support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Pitfalls

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Translating NMPA documentation directly and submitting it without reorganizing the evidence according to the Indonesian pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on commercial or sales grounds, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional material and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so that each country requires a separate effort and both cost and timeline increase.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, model and specification matrix and intended use statements.
• Check whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the local agent's or authorized representative's duties, fees, certificate control and exit mechanism.
• Build a target-country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI's View

AIMEILI recommends that companies treat Indonesian registration not as a one-off document submission but as an overseas market access project. For companies entering several countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster and more stable than filling gaps country by country, and it also supports later changes and renewals.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, a project may still face repeated deficiency responses, agent disputes and post-market maintenance problems, no matter how many documents appear to be available.

Frequently Asked Follow-Up Questions

Can Chinese domestic documentation be used directly for Indonesian registration?

Domestic documentation can serve as a base, but it usually cannot be submitted as is. Companies need to adjust the structure, language, labelling, authorization documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

Start as soon as the target market and product list are confirmed. The earlier the gap assessment is completed, the more time there is to arrange additional testing, translation, label adaptation and agent selection.

Why does the choice of local agent affect registration quality?

The local agent typically takes part in registration communication, variations, renewals and post-market event handling. If duties and rights are unclear, certificate control and the stability of the market after approval can be affected.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project ledger that records the product list, models and specifications, registration pathway, document owners, translation status, testing status, communications with the local agent and expected submission dates in a single table. This makes documentation gaps visible and helps management judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix defining which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent relationship and certificate control.
• Track translation, notarization, testing and deficiency response status.
• Assign post-market maintenance responsibility in advance.

Quality System and Evidence Consistency

From a review perspective, quality system documentation is not an isolated certificate. Regulators usually check whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope of an ISO 13485 certificate does not match the device being registered, or if the manufacturing address, models and specifications or instructions for use version do not match the test reports, additional explanation may be required even if a large volume of documentation has been prepared.

Before submission, companies should build an evidence consistency checklist that maps product name, models and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality system certificate item by item. This step is basic, but it clearly reduces the probability of deficiency letters, particularly for projects covering several GHWP member states or several product families submitted at the same time.

Localization and Agent Responsibility

An Indonesian registration project usually involves arrangements with a local agent, an authorized representative, an importer or a license holder. Companies must confirm in advance whether the local partner only submits documents or also handles regulatory communication, certificate maintenance, post-market incident reporting, variation applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the market after approval.

Labels, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable to the target country, not writing a separate set of documents from scratch.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance; when a manufacturing site change, model extension, instructions for use update or agent replacement occurs, the certificate can become disconnected from actual market sales.

AIMEILI recommends managing this topic within an annual international registration plan: set target market priorities first, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value is not only greater efficiency in a single country; it enables companies to develop repeatable overseas compliance capability and reduces the cost of rebuilding documentation from scratch each time they enter a new market.

Continue Reading

• Previous: How Should a Local Agent for Indonesian Medical Device Registration Be Selected?
• Next: Why Is the Medical Device Registration Timeline in Indonesia Extended?

Recommended reading

• How should documentation be prepared for medical device registration in Malaysia?
• How is product classification determined for medical device registration in Malaysia?
• How should the technical file be organized for medical device registration in Malaysia?
• How should labelling and instructions for use be localized for medical device registration in Malaysia?
• How should clinical evaluation documentation be prepared for medical device registration in Malaysia?
• Can test reports be reused for medical device registration in Malaysia?

Back to the FAQ Centre | News | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Sourcing principle: priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: this article supports preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, test conclusions or legal advice.